Evidence map›Paper›PMID 32813301›Full record

ArticleJournal of clinical laboratory analysis2020

Consistency evaluation of Liferiver, Yaneng, Darui, and the Cobas 4800 test for high-risk human papillomavirus screening.

Mengmeng Wang, Xiang Ji, Xiaowen Dou, Huamei Tang, Lijuan Kan, Wei Wu, Dayang Chen, Zengyan Zong, Dan Xiong, Xiuming Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengmeng WangMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Xiang JiMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Xiaowen DouMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Huamei TangMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Lijuan KanMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Wei WuMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Dayang ChenMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Zengyan ZongMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.ORCID https://orcid.org/0000-0003-2332-4211
Dan XiongMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.
Xiuming ZhangMedical Laboratory of the Third Affiliated Hospital of ShenZhen University, Shenzhen, China.ORCID https://orcid.org/0000-0002-7971-6444

Funding

National Natural Science Foundation of China 81502344National Natural Science Foundation of China 81772921Sanming Project of Medicine in Shenzhen SZSM201601062The discipline construction ability promotion project of Shenzhen health and population family planning commission SZXJ2017018the Science and Technology Planning Project of Shenzhen City of China JCYJ20180306172209668
6 · The paper itself

Abstract

backgroundIn recent years, several high-risk human papillomavirus (HR-HPV) tests have been developed. The assay capabilities need to be systematically reviewed. Here, we compared the clinical sample performance of three novel HR-HPV assays (Liferiver, Yaneng, and Darui) based on different platforms with the widely adopted cobas4800 test.

methodsA total of 346 cervical swabs from women who were screened for cervical cancer were analyzed for the presence of 14 HR-HPV genotypes. The distinction between the four assays was investigated by the genotyping and direct sequencing.

resultsThe positive rates of the four assays ranged from 61.56% to 64.16%. The overall concordance was 88.15%. The Yaneng assays displayed the best sensitivity (100%) and specificity (98.43%). The sensitivity (98.17%) and specificity (98.43%) of the Darui assay were superior to those of the cobas4800 test (97.72% and 93.70%, respectively). The Liferiver assay displayed comparable sensitivity with the cobas4800 test (95.89% and 97.72%, respectively). The specificity of the cobas4800 was lower than that of the Liferiver assay (93.70% vs. 97.64%).

conclusionsThe three novel HR-HPV assays displayed good agreement with the cobas4800 test. The analytical performance of all four fulfilled the requirements of sensitivity and specificity for HR-HPV detection.

Indexed as

Human Papillomavirus DNA TestsFemaleHumansPapillomaviridaePapillomavirus InfectionsReal-Time Polymerase Chain ReactionSensitivity and SpecificityCobas4800 HPV testHR-HPVMassArrayRBD-PCRreal-Time PCR

Identifiers

PMID32813301
PMCPMC7755768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.